ArticleExperimental & applied acarology2026
Synergistic action of piperonyl butoxide with macrocyclic lactones in Rhipicephalus microplus.
Article in Experimental & applied acarology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance of Rhipicephalus microplus to macrocyclic lactones represents a major challenge for the control of this ectoparasite, leading to substantial economic losses. The indiscriminate use of acaricides has resulted in increasingly resistant populations, highlighting the need for alternative control strategies and pharmacological approaches, such as the use of synergists to enhance acaricide efficacy against resistant ticks. This study evaluated the effect of piperonyl butoxide (PBO) as a synergist in modulating resistance to ivermectin, eprinomectin, and moxidectin in five tick populations from the semi-arid area of Northeast Brazil. Bioassays revealed widespread resistance, with variation in LC50 values among locations, likely reflecting differences in the intensity and frequency of macrocyclic lactone use and, consequently, differences in resistance intensity rather than evidence of distinct resistance mechanisms. The association of PBO with macrocyclic lactones resulted in significant synergism in the studied tick populations. A notable reduction in LC50 was observed in 3 out of 5 populations for ivermectin, 4 out of 5 populations for eprinomectin, and 3 out of 5 populations for moxidectin. Even in highly resistant populations to moxidectin, a marked decrease in LC50 was observed after PBO exposure. These results indicate a pharmacological interaction between PBO and macrocyclic lactones, consistent with a partial contribution of oxidative detoxification to the resistance phenotype. However, the absence of synergism in some populations and the persistence of high resistance levels suggest that additional mechanisms are also involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.